Table 4.

AEs Leading to dose reduction

AE, n (%)	Phase 1 dose escalation (all doses) (N=31)	Phase 2- Filanesib (N=32)	Phase 2- Filanesib/Dex (N=55)
AEs leading to dose reduction
Thrombocytopenia	1 (3)	3 (9)	3 (5)
Febrile neutropenia	5 (16)	1 (3)	0 (0)
Mucosal inflammation	5 (16)	1 (3)	0 (0)
Neutropenia	2 (6)	1 (3)	1 (2)
Vomiting	0 (0)	3 (9)	0 (0)
Diarrhea	0 (0)	2 (6)	0 (0)
Pyrexia	0 (0)	2 (6)	0 (0)
Lipase increased	0 (0)	1 (3)	1 (2)
Pneumonia	1 (3)	1 (3)	0 (0)
Leukopenia	1 (3)	0 (0)	0 (0)
Corneal disorder	1 (3)	0 (0)	0 (0)
Vision blurred	1 (3)	0 (0)	0 (0)
Nausea	0 (0)	1 (3)	0 (0)
Blood amylase increased	0 (0)	0 (0)	1 (2)
Bacteremia	0 (0)	1 (3)	0 (0)
Punctate keratitis	0 (0)	1 (3)	0 (0)

This table is based on the safety population.

Abbreviations: AE = adverse event(s); Dex = dexamethasone; N or n = number